Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
September
Previous Archive
29 September 2017
Mineral named after UFS professor
Tredouxite (white) intergrown with bottinoite (light grey), a complex hydrous alteration product. The large host minerals are nickel-rich silicate (grey), maybe willemseite, and the spinel trevorite (dark grey).

More than five thousand minerals have been certified by the International Mineralogical Association(IMA). One of these minerals, tredouxite, was recently named after an academic at the University of the Free State (UFS). 

Tredouxite was named after Prof Marian Tredoux, an associate professor in the Department of Geology, to acknowledge her close to 30 years’ commitment to figuring out the geological history of the rock in which this mineral occurs. The name was chosen by the team which identified the new mineral, consisting of Dr Federica Zaccarini and Prof. Giorgio Garuti from the University of Leoben, Austria, Prof. Luca Bindi from the University of Florence, Italy, and Prof. Duncan Miller from the UFS. 

They found the mineral in the abovementioned rock from the Barberton region in Mpumalanga, in May 2017.

In the past, a mineral was also named after Marie Curie
With the exception of a few historical (pre-1800) names, a mineral is typically named either after the area where it was first found, or after its chemical composition or physical properties, or after a person. If named after a person, it has to be someone who had nothing to do with finding the mineral.

Prof Tredoux said: “As of 19 September 2017, 5292 minerals had been certified by IMA. Of these, 81 were named after women, either singly or with a near relation. Marie Curie is named twice: sklodowskite (herself) and curite (plus husband). Most of the named women are Russian geoscientists.”

Another way to assess the rarity of such a naming is to consider that fewer than 700 minerals have been named after people. Given that there are by now seven billion people on the planet, it means that a person who is granted a mineral name becomes one in 10 million of the people alive today to be honoured in such a way. To date, over a dozen minerals had been named after South Africans, three of them after women (including tredouxite).

It contains nickel, antimony and oxygen
The chemical composition of tredouxite is NiSb2O6 (nickel antimony oxide). This makes it the nickel equivalent of the magnesium mineral bystromite (MgSb2O6), described in the 1950s from the La Fortuna antimony mine in Mexico.  

“This announcement is of great academic importance: the discovery by the Italian team of a phase with that specific chemical composition will undoubtedly help me and my co-workers to better understand the origin of the rock itself,” she said. She also expressed the hope that it may raise interest in the Department of Geology and the UFS as a whole, by highlighting that world-class research is being done at the department. 

The announcement of this new mineral was published on the International Mineralogical Association Commission on New Minerals, Nomenclature and Classificationwebsite, the Mineralogical Magazine and the European Journal of Mineralogy.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept